Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Total Debt: 2021-2024

Historic Total Debt for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Dec 2024 value amounting to $107.2 million.

  • Arcutis Biotherapeutics' Total Debt fell 46.97% to $108.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.5 million, marking a year-over-year decrease of 46.97%. This contributed to the annual value of $107.2 million for FY2024, which is 46.88% down from last year.
  • As of FY2024, Arcutis Biotherapeutics' Total Debt stood at $107.2 million, which was down 46.88% from $201.8 million recorded in FY2023.
  • Arcutis Biotherapeutics' Total Debt's 5-year high stood at $201.8 million during FY2023, with a 5-year trough of $72.3 million in FY2021.
  • For the 3-year period, Arcutis Biotherapeutics' Total Debt averaged around $168.9 million, with its median value being $197.8 million (2022).
  • Its Total Debt has fluctuated over the past 5 years, first spiked by 173.35% in 2022, then crashed by 46.88% in 2024.
  • Over the past 4 years, Arcutis Biotherapeutics' Total Debt (Yearly) stood at $72.3 million in 2021, then spiked by 173.35% to $197.8 million in 2022, then climbed by 2.04% to $201.8 million in 2023, then plummeted by 46.88% to $107.2 million in 2024.